New York, Feb 15, 2026, 14:37 EST — Market closed
- AbbVie finished Friday up 1.8% at $231.50 a share.
- U.S. markets are closed Monday for Presidents Day. Trading picks back up on Tuesday.
- AbbVie’s drug-pricing moves and pipeline updates are in focus for investors, set against a week dominated by broader macro themes.
AbbVie Inc (ABBV.N) finished Friday at $231.50, up 1.8%. The stock moved between $227.33 and $234.69 over the session.
Looking ahead to a shortened week, the stock faces a pause as U.S. markets shut down Monday for Presidents Day. Regular trading is back Tuesday. (MarketWatch)
The calendar gets busy: a batch of market-shaking events is on deck for the next several sessions. Investors are bracing for Federal Reserve minutes on Wednesday, then a string of data covering inflation, growth, and housing dropping as the week rolls on. (Federal Reserve)
The S&P 500 managed a small gain Friday, but the Nasdaq dipped as big tech names lost ground. “Large cap tech stocks continue to be an anchor on the market,” said Michael James, managing director at Rosenblatt Securities. (Reuters)
AbbVie saw heavier-than-usual trading volume and the shares are still roughly 5% off their 52-week peak, according to MarketWatch. The stock pulled ahead of Johnson & Johnson for the session. Pfizer and Amgen ended up.
AbbVie is still locked in a debate over how well it can pivot from its long-time blockbuster, Humira, after the drug’s U.S. patent expired and biosimilar rivals moved in. Earlier this month, the company’s earnings landed with a miss on sales for Rinvoq, a newer immunology option, adding to investors’ nerves about rising competition. As William Blair’s Matt Phipps put it, “Investors continue to have concerns about growing competition.” (Reuters)
In its February earnings release, AbbVie pegged full-year 2025 net revenues at $61.160 billion, while adjusted earnings guidance for 2026 landed between $14.37 and $14.57 per share—those adjusted figures exclude specific one-offs. “2025 was another outstanding year for AbbVie,” CEO Robert A. Michael said in the announcement. (AbbVie News Center)
AbbVie, in that same update, revealed a three-year pact with the Trump administration. The deal includes lower Medicaid prices, broader direct-to-patient options, and a pledge: $100 billion earmarked for U.S. R&D and capital spending over the next ten years. AbbVie also noted the agreement spares it from tariffs and shields it from any future pricing mandates. (AbbVie News Center)
The company is working to widen Rinvoq’s label too. Separately, AbbVie announced it had submitted a filing to U.S. and European authorities seeking a new indication for vitiligo, pointing out that no systemic treatments are currently cleared for the disease. “Many patients experience ongoing frustration,” said Kori Wallace, who oversees immunology development at AbbVie. (AbbVie News Center)
Drug pricing is still a flashpoint. AbbVie has taken legal action against the U.S. Department of Health and Human Services, challenging the decision to include Botox in Medicare’s drug price negotiation program. The company maintains Botox shouldn’t be on the list; the suit also targets HHS Secretary Robert F. Kennedy Jr., CMS administrator Mehmet Oz, and others. Botox made up a bit more than 10% of AbbVie’s yearly sales, according to Reuters. (Reuters)
Here’s the risk: Litigation tends to drag on, and a negative court decision might weigh on the company’s aesthetics and neuroscience cash streams. Investors are already focused on any signs of weakness in the Skyrizi-Rinvoq growth story.
Looking to the days ahead, ABBV resumes trading Tuesday; investors are eyeing the Fed minutes due Wednesday, plus some major inflation and growth data set for later in the week. As for earnings, Wall Street penciled in AbbVie’s next release for about April 24, but there’s no official word from the company yet. (Zacks)
